Biotech Values

[rkrw]

I was at R&R. Missed the genr presentation as I took an early aft train home.

I did see BPA. ceo made an interesting comment about vvus whom he doesn't seem so worried about. Said drugs changing female sexual desire are difficult and pointed to the viagra fsd failure. Said fda endpt is about sexual events and bpa data is very strong. Data will be out sat. and he as much as said we will be impressed. He even did a demonstration of libigel, squirting a dose on his hand and rubbing it in.

Other comments, cgtk, I think it's way too risky to be long heading into the data. May even be a good short, but probably too unpredictable for me.

orph, I think drbio is on to a potential winner, albeit I don't see xyrem as having massive potential. ceo said breakeven is at around $50M in sales. So it may not take much to drive this.

Least impressive I saw was RGEN ceo. He said the U.Michigan patent claims come from telephone conversations and nothing was written or documented. Can anyone confirm this is the case for both patent disputes (rgen already lost one)? Maybe he was just referring to the first case. Very strange. Second most unimpressive was ency cfo. I've seen the ceo present before and he's quite good. cfo didn't have appropriate answers for many questions.